Antineoplastic combined chemotherapy protocols. Medical search

The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)

The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.

An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.

Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.

An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)

Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.

A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.

A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.

Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.

Precise and detailed plans for the study of a medical or biomedical problem and/or plans for a regimen of therapy.

Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.

Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.

A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Tumors or cancer of the human BREAST.

New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.

A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)

Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.

A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.

Antimetabolites that are useful in cancer chemotherapy.

Tumors or cancer of the LUNG.

An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.

A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.

Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.

The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.

Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.

Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

An organoplatinum compound that possesses antineoplastic activity.

A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.

Elements of limited time intervals, contributing to particular results or situations.

A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.

A cell line derived from cultured tumor cells.

Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Organic compounds which contain platinum as an integral part of the molecule.

Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.

Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.

The relationship between the dose of an administered drug and the response of the organism to the drug.

The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.

Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.

One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.

Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.

A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.

Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.

The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)

Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.

A malignant epithelial tumor with a glandular organization.

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

The forcible expulsion of the contents of the STOMACH through the MOUTH.

Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.

An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.

An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.

The action of a drug in promoting or enhancing the effectiveness of another drug.

Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.

Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.

A decrease in the number of NEUTROPHILS found in the blood.

Neoplasm drug therapy involving an extracorporeal circuit with temporary exclusion of the tumor-bearing area from the general circulation during which high concentrations of the drug are perfused to the isolated part.

A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.

An alkylating agent of value against both hematologic malignancies and solid tumors.

The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.

An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.

The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.

Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.

Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.

An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)

The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.

An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.

Transplantation of an individual's own tissue from one site to another site.

Tumors or cancer located in bone tissue or specific BONES.

Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.

Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.

An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.

An anthracenedione-derived antineoplastic agent.

A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.

In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.

Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.

Clinical protocols used to inhibit the growth or spread of NEOPLASMS.

Tumors or cancer of the LIVER.

Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.

An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.

A general term for various neoplastic diseases of the lymphoid tissue.

A rare, metallic element designated by the symbol, Ga, atomic number 31, and atomic weight 69.72.

Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.

Tumors or cancer of the COLON.

Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.

A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)

A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)

All of the processes involved in increasing CELL NUMBER including CELL DIVISION.

Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.

A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)

A group of 20-member macrolactones in which there are three remotely substituted pyran rings that are linked by a methylene bridge and an E-disubstituted alkene, and have geminal dimethyls at C8 and C18 carbons. Some interact with PROTEIN KINASE C.

Pyrido-CARBAZOLES originally discovered in the bark of OCHROSIA ELLIPTICA. They inhibit DNA and RNA synthesis and have immunosuppressive properties.

Phospholipids which have an alcohol moiety in ethereal linkage with a saturated or unsaturated aliphatic alcohol. They are usually derivatives of phosphoglycerols or phosphatidates. The other two alcohol groups of the glycerol backbone are usually in ester linkage. These compounds are widely distributed in animal tissues.

A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.

Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.

An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.

Antibodies produced by a single clone of cells.

The return of a sign, symptom, or disease after a remission.

Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.

Inorganic compounds which contain platinum as the central atom.

Coverings for the hands, usually with separations for the fingers, made of various materials, for protection against infections, toxic substances, extremes of hot and cold, radiations, water immersion, etc. The gloves may be worn by patients, care givers, housewives, laboratory and industrial workers, police, etc.

Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.

The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.

Simultaneous resistance to several structurally and functionally distinct drugs.

A nursing specialty concerned with the care provided to cancer patients. It includes aspects of family functioning through education of both patient and family.

Drugs used to prevent NAUSEA or VOMITING.

Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.

Experimental transplantation of neoplasms in laboratory animals for research purposes.

A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).

Tumors or cancer of the PERITONEUM.

The total amount of radiation absorbed by tissues as a result of radiotherapy.

The use of DRUGS to treat a DISEASE or its symptoms. One example is the use of ANTINEOPLASTIC AGENTS to treat CANCER.

A subnormal level of BLOOD PLATELETS.

Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.

Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed)

Tumors or cancer of the STOMACH.

Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.

Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms.

Alkaloids derived from TYRAMINE combined with 3,4-dihydroxybenzaldehyde via a norbelladine pathway, including GALANTAMINE, lycorine and crinine. They are found in the Amaryllidaceae (LILIACEAE) plant family.

A malignant neoplasm of the germinal tissue of the GONADS; MEDIASTINUM; or pineal region. Germinomas are uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular eosinophilic-staining cytoplasm. (Stedman, 265th ed; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1642-3)

Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.

Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)

Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.

A plant genus of the family LILIACEAE. Members contain ungiminorine and LECTINS.

A 170-kDa transmembrane glycoprotein from the superfamily of ATP-BINDING CASSETTE TRANSPORTERS. It serves as an ATP-dependent efflux pump for a variety of chemicals, including many ANTINEOPLASTIC AGENTS. Overexpression of this glycoprotein is associated with multidrug resistance (see DRUG RESISTANCE, MULTIPLE).

The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.

A plant genus of the family ASTERACEAE. This plant should not be confused with microtubule asters (MICROTUBULES) nor with aster yellows phytoplasma (mycoplasma-like organisms).

The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.

The exposure to potentially harmful chemical, physical, or biological agents that occurs as a result of one's occupation.

A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)

Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.

A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.

A plan for collecting and utilizing data so that desired information can be obtained with sufficient precision or so that an hypothesis can be tested properly.

Histochemical localization of immunoreactive substances using labeled antibodies as reagents.

A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.

A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.

A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.

An anti-inflammatory 9-fluoro-glucocorticoid.

The giving of drugs, chemicals, or other substances by mouth.

Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.

Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).

Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs.

Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work.

A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).

Compounds with 1,2-diphenylethane. They are structurally like reduced STILBENES.

Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS.

Treatment that combines chemotherapy with radiotherapy.

Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).

A small plant family of the order Santalales, subclass Rosidae, class Magnoliopsida.

Cyclic hydrocarbons that contain multiple rings and share one or more atoms.

A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.

Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.

Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.

An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.

An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.

Treatment designed to help prevent a relapse of a disease following the successful primary treatments (INDUCTION CHEMOTHERAPY and CONSOLIDATION CHEMOTHERAPY) with a long-term low-dose drug therapy.

The exposure of the head to roentgen rays or other forms of radioactivity for therapeutic or preventive purposes.

A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.

Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.

Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.

Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)

Platinum. A heavy, soft, whitish metal, resembling tin, atomic number 78, atomic weight 195.09, symbol Pt. (From Dorland, 28th ed) It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae".

Individuals responsible for various duties pertaining to the medical office routine.

The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture.

A subspecialty of internal medicine concerned with the study of neoplasms.

Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)

In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.

Tumors or cancer of the PROSTATE.

The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds.

A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.

The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.

Tomography using x-ray transmission and a computer algorithm to reconstruct the image.

Proteins prepared by recombinant DNA technology.

Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure. Large cyclic lactones of over a dozen atoms are MACROLIDES.

Devices designed to provide personal protection against injury to individuals exposed to hazards in industry, sports, aviation, or daily activities.

The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.

An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.

Compounds consisting of chains of AMINO ACIDS alternating with CARBOXYLIC ACIDS via ester and amide linkages. They are commonly cyclized.

The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.

Antagonist of urate oxidase.

Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.

Functions and activities of DENTITION as a whole.

The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.

Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.

Antibodies obtained from a single clone of cells grown in mice or rats.

Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.

A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.

A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)

Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.

Tumour ablation and hepatic decompensation rates in multi-agent chemoembolization of hepatocellular carcinoma. (1/20433)

Thirty-seven cirrhotic patients with 62 hepatocellular carcinoma (HCC) foci--most Child-Pugh class B or C and/or with large, inoperable tumours--underwent 148 sessions of transcatheter arterial chemoembolization (TACE) using lipiodol, doxorubicin and cisplatin. Treatment efficacy was assessed by serial hepatic arteriography in 34/37 (91.9%) patients and abdominal CT scanning in 3/37 (8.1%) patients. Child-Pugh status was determined prior to each treatment session. Varying degrees of control of tumour neovascularity occurred for a median 390 days (range 90 to > 1680 days) in 33/34 (97.1%) patients in whom progress hepatic arteriography was performed. Ablation of tumour neovascularity occurred in 6/6 (100%), 4/12 (33.3%) and 6/16 (37.5%) patients with HCC diameters < 4 cm, 4-7 cm and > 8 cm, respectively (p < 0.02). Significantly more sessions were required for ablation of larger tumours (p < 0.05). Recurrent HCC was detected in 50% of patients after a median 240 days (range 60-1120 days). Deterioration in Child-Pugh status followed a session of TACE on 19/148 (12.8%) occasions but resulted in unscheduled hospitalization on only 4/148 (2.7%) occasions, the highest incidence (8.3%) in Child-Pugh C patients. Actuarial survival was 27/36 (75.0%) at 6 months, 17/34 (50.0%) at 12 months, 14/34 (41.2%) at 18 months, 9/31 (29.0%) at 24 months and 4/27 (14.8%) at 36 months. Multi-agent TACE with lipiodol, doxorubicin and cisplatin provides a useful anti-tumour effect, even in cirrhotic patients with large HCCs. The incidence of clinically significant deterioration in hepatic function due to ischaemia of non-tumorous liver is acceptably low, even in Child-Pugh C patients. (+info)

Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). (2/20433)

Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m(-2), 5-fluorouracil 500 mg m(-2), epidoxorubicin 35 mg m(-2), 6S stereoisomer of leucovorin 250 mg m(-2) and glutathione 1.5 mg m(-2), supported by a daily administration of lenograstim at a dose of 5 microg kg(-1). Nineteen patients were men and three were women. Median age was 63 years (range 47-70). At study entry, pain was present in 15 out of 22 patients (68%) with a mean value of Scott-Huskisson scale of 27.6+/-23.8, whereas a weight loss >10% was present in 15 patients. After eight weekly treatments, three partial responses were achieved for a response rate of 13% (95% CI 0-26%), five patients had stable disease and 14 progressed on therapy. Pain was present in 9 out of 22 patients (40%) with a mean value of Scott-Huskisson scale of 12.3+/-18.4. Eight patients (36%) (three partial response and five stable disease) had a positive weight change. Toxicity was mild: WHO grade III or IV toxicity was recorded in terms of anaemia in 7 out of 188 cycles (3.7%), of neutropenia in 9 out of 188 cycles (4.7%) and of thrombocytopenia in 3 out of 188 cycles (1.5%). Median survival of all patients was 6 months. The outcome of this intensive chemotherapy regimen does not support its use in pancreatic cancer. (+info)

Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. (3/20433)

Based on an increased frequency of early death (death within the first treatment cycle) in our two latest randomized trials of combination chemotherapy in small-cell lung cancer (SCLC), we wanted to identify patients at risk of early non-toxic death (ENTD) and early toxic death (ETD). Data were stored in a database and logistic regression analyses were performed to identify predictive factors for early death. During the first cycle, 118 out of 937 patients (12.6%) died. In 38 patients (4%), the cause of death was sepsis. Significant risk factors were age, performance status (PS), lactate dehydrogenase (LDH) and treatment with epipodophyllotoxins and platinum in the first cycle (EP). Risk factors for ENTD were age, PS and LDH. Extensive stage had a hazard ratio of 1.9 (P = 0.07). Risk factors for ETD were EP, PS and LDH, whereas age and stage were not. For EP, the hazard ratio was as high as 6.7 (P = 0.0001). We introduced a simple prognostic algorithm including performance status, LDH and age. Using a prognostic algorithm to exclude poor-risk patients from trials, we could minimize early death, improve long-term survival and increase the survival differences between different regimens. We suggest that other groups evaluate our algorithm and exclude poor prognosis patients from trials of dose intensification. (+info)

Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. (4/20433)

Dihydropyrimidine dehydrogenase (DPD) is responsible for the breakdown of the widely used antineoplastic agent 5-fluorouracil (5FU), thereby limiting the efficacy of the therapy. To identify patients suffering from a complete or partial DPD deficiency, the activity of DPD is usually determined in peripheral blood mononuclear cells (PBM cells). In this study, we demonstrated that the highest activity of DPD was found in monocytes followed by that of lymphocytes, granulocytes and platelets, whereas no significant activity of DPD could be detected in erythrocytes. The activity of DPD in PBM cells proved to be intermediate compared with the DPD activity observed in monocytes and lymphocytes. The mean percentage of monocytes in the PBM cells obtained from cancer patients proved to be significantly higher than that observed in PBM cells obtained from healthy volunteers. Moreover, a profound positive correlation was observed between the DPD activity of PBM cells and the percentage of monocytes, thus introducing a large inter- and intrapatient variability in the activity of DPD and hindering the detection of patients with a partial DPD deficiency. (+info)

Patterns of care and survival for adolescents and young adults with acute leukaemia--a population-based study. (5/20433)

We report a population-based study of patterns of care and survival for people with acute leukaemia diagnosed at age 15-29 years during 1984-94 in regions of England and Wales covered by specialist leukaemia registries. There were 879 patients: 417 with acute lymphoblastic leukaemia (ALL) and 462 with acute myeloid leukaemia (AML). For ALL, actuarial survival rates were 43% at 5 years after diagnosis and 37% at 10 years. Survival improved significantly between 1984-88 and 1989-94 for those aged 15-19 at diagnosis. Patients entered in national clinical trials and those not entered had similar survival rates. Survival rates were similar at teaching and non-teaching hospitals and at hospitals treating different numbers of study patients per year. For AML, survival rates were 42% at 5 years after diagnosis and 39% at 10 years. Survival improved significantly between 1984-88 and 1989-94. Patients entered in the Medical Research Council AML10 trial had a higher survival rate than those who were in the earlier AML9 trial. Survival did not vary with category of hospital. We conclude that survival has improved for adolescents and young adults with acute leukaemia but that there is at present no evidence that centralized treatment results in a survival benefit for patients in this age group. (+info)

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (6/20433)

We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients. (+info)

Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. (7/20433)

The effect of an extensive prophylactic antimicrobial regimen was prospectively assessed in 126 patients after high-dose chemotherapy and autologous PBSC. They received ciprofloxacin (500 mg/12 h), acyclovir (200 mg/6 h), and itraconazole (200 mg/12 h) orally until neutrophil recovery. Febrile patients received i.v. imipenem (500 mg/6 h) to which vancomycin and amikacin were added if fever persisted for 2-3 and 5 days, respectively. Amphotericin B lipid complex was further given on day 7 or 8 of fever. Median times for a neutrophil count of >0.5 x 10(9)/l and a platelet count of >20 x 10(9)/l were 9 and 11 days. Severe neutropenia (<0.1 x 10(9)/l) lasted for a median of 5 days in which 72% of febrile episodes and 50% of cases of bacteremia occurred. Gram-positive bacteria were isolated in 30 of 40 episodes of bacteremia, 25 of which were caused by Staphylococcus epidermidis. Clinical foci were the intravascular catheter in 35 cases, respiratory infection in 11, cellulitis in two, anal abscess in one, and neutropenic enterocolitis in one. The high incidence of febrile episodes (94%) and bacteremias (31%) may be due to the lack of efficacy of antimicrobial prophylaxis and the persistence of a 5-day period of severe neutropenia. (+info)

Central venous catheter exchange by guidewire for treatment of catheter-related bacteraemia in patients undergoing BMT or intensive chemotherapy. (8/20433)

Current guidelines for the treatment of catheter-related bacteraemia (CRB) advise against central venous catheter (CVC) exchange because of the potential risk of prolonging infection. However, there are no consistent data proving this recommendation. We evaluated prospectively the usefulness of CVC exchange by guidewire for the treatment of CRB in patients undergoing BMT or intensive chemotherapy. CVC exchange was considered when fever and positive blood cultures persisted after 2 days of adequate antimicrobial therapy and no potential source of bacteraemia other than CVC could be identified. The guidewire exchange was preceded and followed by a slow infusion of adequate antimicrobial therapy. Bacteraemia was confirmed as catheter-related by demonstrating concordance between isolates from the tip and blood cultures by pulsed-field electrophoresis of genomic DNA. This procedure was performed in 19 episodes of bacteraemia during a 1-year period. Fourteen episodes (74%) were catheter-related and 71% of these were due to coagulase-negative staphylococci. Guidewire replacement was accomplished uneventfully 4 days after development of sepsis (range 3-6). In all cases, clinical signs of sepsis disappeared in less than 24 h after replacement. Definitive catheter withdrawal was carried out a median of 16 days (range 3-42) after guidewire exchange; in all cases, the tip culture was negative. We conclude that CVC replacement by guidewire under adequate antimicrobial therapy may be a reasonable option for the treatment of CRB when antimicrobial therapy alone has been unsuccessful. (+info)

... antineoplastic combined chemotherapy protocols MeSH E02.190.044.080 - acupressure MeSH E02.190.044.105 - acupuncture analgesia ... antineoplastic combined chemotherapy protocols MeSH E02.319.162.150 - antibiotic prophylaxis MeSH E02.319.300.253 - delayed- ... antineoplastic combined chemotherapy protocols MeSH E02.319.310.075 - antiretroviral therapy, highly active MeSH E02.319. ...

https://en.wikipedia.org/wiki/List_of_MeSH_codes_(E02)

The FLAMSA protocol is most often used as an induction part of a reduced-intensity conditioning regimen for patients eligible ... G-CSF is still included, even though the "G" is taken out of the acronym.) Amsacrine is an alkylating antineoplastic agent that ... In this setting, it is often combined with other agents, such as: Cyclophosphamide (FLAMSA-CYC), and/or Busulfan or treosulfan ... FLAG is a chemotherapy regimen used for relapsed and refractory acute myeloid leukemia (AML). The acronym incorporates the ...

https://en.wikipedia.org/wiki/FLAG_(chemotherapy)

... is a chemotherapy regimen used in the first-line treatment of Hodgkin lymphoma, replacing the older MOPP protocol. It ... January 1987). "Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus ... www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/gastrointestinal/7-prevention-of-antineoplastic-induced- ... All four of the chemotherapy drugs are given intravenously. ABVD chemotherapy is usually given in the outpatient setting - that ...

https://en.wikipedia.org/wiki/ABVD

Springer Protocols. pp. 405-432.. *^ Luqmani YA (2005). "Mechanisms of drug resistance in cancer chemotherapy". Medical ... Combined modality chemotherapy is the use of drugs with other cancer treatments, such as surgery, radiation therapy, or ... Main article: List of antineoplastic agents. There is an extensive list of antineoplastic agents. Several classification ... Intensification chemotherapy is identical to consolidation chemotherapy but a different drug than the induction chemotherapy is ...

https://en.wikipedia.org/wiki/Chemotherapeutics

This type of chemotherapy is used for curative intent. Combined modality chemotherapy is the use of drugs with other cancer ... In the 1970s, antineoplastic (chemotherapy) drugs were identified as hazardous, and the American Society of Health-System ... Generating Inhibitors of P-Glycoprotein: Where to, Now?. Springer Protocols. pp. 405-432. Luqmani YA (2005). "Mechanisms of ... Intensification chemotherapy is identical to consolidation chemotherapy but a different drug than the induction chemotherapy is ...

https://en.wikipedia.org/wiki/Chemotherapy

Aprepitant combined with ondansetron and dexamethasone has been shown to be better for highly emetogenic chemotherapy than just ... The new protocol that he developed led to a marked increase in disease-free survival rates for patients with medulloblastoma, ... Cisplatin is in the platinum-based antineoplastic family of medications. It works in part by binding to DNA and inhibiting its ... Cisplatin is a chemotherapy medication used to treat a number of cancers. These include testicular cancer, ovarian cancer, ...

https://en.wikipedia.org/wiki/Cisplatin

See also: Antineoplastic resistance. A major cause for the ineffectiveness of current chemotherapy treatments is multiple drug ... Synthetic protocols for silver nanoparticle production can be modified to produce silver nanoparticles with non-spherical ... second approach is to attach a chemotherapeutic drug directly to the functionalized surface of the silver nanoparticle combined ... Chemotherapy[edit]. The introduction of nanotechnology into medicine is expected to advance diagnostic cancer imaging and the ...

https://en.wikipedia.org/wiki/Silver_nanoparticle

The chemotherapy used was Cisplatin or Carboplatin, combined with Gemcitabine for patient with squamous cell NSCLC, or ... with cisplatin or carboplatin as the backbone of all the chemotherapy treatments protocols. Pemetrexed is provided with ... and approved pembrolizumab in combination with pemetrexed and platinum-based antineoplastic (carboplatin or cisplatin) as first ... chemotherapy plus atezolizumab or chemotherapy plus Bevacizumab and atezolizumab. The chemotherapy used was Carboplatin, and ...

https://en.wikipedia.org/wiki/Treatment_of_lung_cancer

Helgstrand E, Oberg B (1980). "Enzymatic targets in virus chemotherapy". Virus Chemotherapy. Antibiotics and Chemotherapy. 27. ... This may also be combined with radioactivity to achieve apoptosis of malignant cells. Some antiviral drugs, such as acyclovir ( ... 2015). "Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2 ... Cold Spring Harbor Protocols. 2016 (2): pdb.prot085118. doi:10.1101/pdb.prot085118. PMID 26832684. Sun R, Eriksson S, Wang L ( ...

https://en.wikipedia.org/wiki/Thymidine_kinase

"The purine path to chemotherapy. Nobel Lecture 1988". Black J. "Drugs from emasculated hormones: the principles of synoptic ... Some descriptors such as ligand efficiency (LE) and lipophilic efficiency (LiPE) combine such parameters to assess druglikeness ... For certain therapy areas, such as antimicrobials, antineoplastics, antihypertensive and anti-inflammatory drugs, the numbers ... agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis". Bioorganic & Medicinal Chemistry Letters ...

https://en.wikipedia.org/wiki/Drug_discovery

The combined high prevalence of rates of aflatoxin and hepatitis B in settings such as China and West Africa has led to ... Mipsagargin (G-202), has orphan drug designation as a treatment during chemotherapy for HCC. It is a thapsigargin-based prodrug ... Controversy remains as to the most effective screening protocols. For example, while some data support decreased mortality ... "Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells". Biochemical ...

https://en.wikipedia.org/wiki/Hepatocellular_carcinoma

Refractory chemotherapy-induced nausea and vomiting; anorexia; neuropathic pain.. Dizziness, euphoria, paranoia, somnolence, ... Smith, Howard S.; Raffa, Robert B.; Pergolizzi, Joseph V.; Taylor, Robert; Tallarida, Ronald J. (2014-07-01). "Combining opioid ... "Should New Zealand continue signing up to the Pethidine Protocol?" (PDF). The New Zealand Medical Journal. 119 (1230): U1875. ...

https://en.wikipedia.org/wiki/Analgetics

https://en.wikipedia.org/wiki/Algesic

Protocols Source:http://linkedlifedata.com/resource/pubmed/meshheading/3204009-Antineoplastic+Combined+Chemotherapy+Protocols ... 3204009-Antineoplastic+Combined+Chemotherapy+ ...

http://linkedlifedata.com/resource/pubmed-meshheading/3204009-Antineoplastic%2BCombined%2BChemotherapy%2BProtocols

Antineoplastic Combined Chemotherapy Protocols. *Drug: Cesamet™ (nabilone). Interventional. Phase 4. *NEMA Research, Inc. ... A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting. *Nausea and ... Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy. *Peripheral ... To demonstrate incremental improvement with Cesamet in control of chemotherapy induced nausea and vomiting in patients who have ...

https://clinicaltrials.gov/ct2/results?term=nabilone+OR+cesamet+AND+Antiemetics

Antineoplastic Combined Chemotherapy Protocols. Paclitaxel. Cisplatin. Additional relevant MeSH terms: Lung Neoplasms. ... Antineoplastic Agents, Phytogenic. Antineoplastic Agents. Tubulin Modulators. Antimitotic Agents. Mitosis Modulators. Molecular ... Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer. The safety and ... Effect of Chemotherapy With Paclitaxel and Cisplatin on Development Dysgeusia in Non-small Cell Lung Cancer Patients. ...

https://clinicaltrials.gov/ct2/show/NCT01540045

PURPOSE: The combination of sorafenib with chemotherapy is well-tolerated and is associated with encouraging response rates in ... Antineoplastic Combined Chemotherapy Protocols. *Antineoplastic Combined Chemotherapy Protocols: th. *Benzenesulfonates. * ... A phase II study was conducted to determine the efficacy and toxicity of combined sorafenib, docetaxel, and cisplatin in ... PURPOSE: The combination of sorafenib with chemotherapy is well-tolerated and is associated with encouraging response rates in ...

https://www.mendeley.com/research-papers/phase-ii-study-sorafenib-combination-docetaxel-cisplatin-treatment-metastatic-advanced-gastric-gastr/

Antineoplastic Combined Chemotherapy Protocols / adverse effects * Antineoplastic Combined Chemotherapy Protocols / therapeutic ... However, recently, a regimen combining fluorouracil, irinotecan, oxaliplatin, and leucovorin (FOLFIRINOX) and another combining ... In addition, PDAC cells promote a dense functional stroma that facilitates tumor resistance to chemotherapy and radiation. ... Keywords: Adoptive T cell therapy; Antibody therapy; Biomarkers; Chemotherapy; Immune surveillance; Immunotherapy; Inhibitors; ...

https://pubmed.ncbi.nlm.nih.gov/26309356/

This study has identified pathway specific prognostic biomarkers possibly underlying a differential chemotherapy response in ... Antineoplastic Combined Chemotherapy Protocols / therapeutic use* * Carcinoma, Ovarian Epithelial * Cluster Analysis * Drug ... Background: Resistance to platinum-based chemotherapy remains a major impediment in the treatment of serous epithelial ovarian ... Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment ...

https://pubmed.ncbi.nlm.nih.gov/24237932/

Keywords : Leukemia, lymphoid; Antineoplastic combined chemotherapy protocols; Immunization; Viral vaccines; Child. · text in ... RESULTS: After chemotherapy, 75.9%, 67.9%, 59.3% and 51.7% of the patients showed low antibody titers that would be unlikely to ... OBJECTIVE: To evaluate viral vaccine antibody levels in children with acute lymphoblastic leukemia after chemotherapy and after ... Antibody responses to Hepatitis B and measles-mumps-rubella vaccines in children who received chemotherapy for acute ...

http://www.scielo.br/scielo.php?script=sci_abstract&pid=S1516-84842012000400011&lng=en&nrm=iso&tlng=en

Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Carcinoma, Non-Small-Cell Lung /drug therapy / ... Combine searches by placing the search numbers in the top search box and pressing the search button.. An example search might ... 17.T reatment with high-dose chemotherapy outside II 314, 315 6.2 of clinical trials is not recommended. 18.Women should be ... Received steroid therapy with in 7 days prior to 1st dose of study drug for anti-neoplastic intent. Received any anti (...) and ...

https://www.tripdatabase.com/search?criteria=Clinical+Index+of+Stable+Febrile+Neutropenia&page=20

Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis / drug effects*. Breast Neoplasms / drug therapy, ... Title: Cancer chemotherapy and pharmacology Volume: 66 ISSN: 1432-0843 ISO Abbreviation: Cancer Chemother. Pharmacol. ...

http://www.biomedsearch.com/nih/novel-small-molecule-inhibitor-potentiates/20012863.html

Antineoplastic Combined Chemotherapy Protocols / pharmacology*. Cell Death / drug effects. Cells, Cultured. Dose-Response ... The role of IRS1 and IRS2 in controlling cell responses to chemotherapy is unknown. To determine the role of IRS1 and IRS2 in ... We found that expression of IRS1, in contrast to IRS2, enhanced the sensitivity of 32D cells to chemotherapy-induced apoptosis ... Decreasing Annexin A2 levels reduced 32D-IRS1 cell sensitivity to chemotherapy. These results suggest IRS1 enhances sensitivity ...

http://www.biomedsearch.com/nih/Insulin-receptor-substrate-1-expression/22652453.html

Antineoplastic Combined Chemotherapy Protocols [administration & dosage]; Cyclophosphamide [administration & dosage]; ... DUARTE, Bruno Kosa Lino et al. Brazilian experience using high dose sequential chemotherapy followed by autologous ... Chemotherapy consisted of the sequential administration of high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte-colony ... OBJECTIVE: To evaluate the use of high-dose sequential chemotherapy in a Brazilian population. METHODS: High-dose ...

http://www.scielo.br/scielo.php?script=sci_abstract&pid=S1516-84842011000600011&lng=pt&nrm=iso&tlng=en

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS - therapeutic use; CISPLATIN - therapeutic use; COMBINED MODALITY THERAPY; ... Adjuvant sandwich chemotherapy plus radiotherapy vs adjuvant chemotherapy alone for locally advanced bladder cancer after ... Combined Positive Score) mora biti ≥ 10. Imunoterapija se može primijeniti bez obzira na razinu izraženosti PD-L1 u bolesnika ... Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in ...

https://hrcak.srce.hr/index.php?show=clanak&id_clanak_jezik=338730

Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Head and Neck Neoplasms ...

https://medicine.yale.edu/cancer/patient/programs/thoracic/members/

Antineoplastic Combined Chemotherapy Protocols. 1. 2014. 9799. 0.140. Why? Mutation. 2. 2014. 26651. 0.130. Why? ...

https://connects.catalyst.harvard.edu/Profiles/display/person/52787/network/researchareas/details

Antineoplastic Combined Chemotherapy Protocols. *Breast Neoplasms. *Neoplasms. *Lung Neoplasms. *Ovarian Neoplasms. *Prostatic ... Chemotherapy, radiation therapy, immunotherapy, or systemic biologic. - anticancer therapy within 21 days before beginning ... progressed during or after one or more chemotherapy regimens; Metastatic breast. cancer; Hormone-refractory prostate cancer; ...

http://www.knowcancer.com/cancer-trials/NCT00080041/

Antineoplastic Combined Chemotherapy Protocols. *Pelvic Exenteration. *Pelvic Neoplasms. *Chemotherapy, Cancer, Regional ... In Combination With And/or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer ... or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy ... Versus Investigators Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, ...

http://medicine.yale.edu/intranet/facultybydept/dan-arin_silasi-3.profile

Antineoplastic Combined Chemotherapy Protocol. *Neoplasms. .map{width:100%;height:300px;margin-bottom:15px}. Name. Location. ... Concurrent treatment with any other anticancer therapy, including chemotherapy,. immunotherapy, radiotherapy (excluding ...

http://www.knowcancer.com/cancer-trials/NCT00719524/

Antineoplastic combined chemotherapy protocols; Chemotherapy, adjuvant; Combined modality therapy; Neoplasm staging; Neoplasm ... Irinotecan combined with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised ... Jalil O, Claydon L, Arulampalam T. Review of neoadjuvant chemotherapy alone in locally advance rectal cancer. J Gastrointest ... American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22 ...

https://hrcak.srce.hr/index.php?show=clanak&id_clanak_jezik=306805

Antineoplastic Combined Chemotherapy Protocols (administration & dosage) *Arsenicals (administration & dosage) *Cytarabine ( ...

http://www.curehunter.com/public/pubmed20705755.do

Antineoplastic Combined Chemotherapy Protocols (therapeutic use) *Cause of Death. *Cisplatin (administration & dosage) ...

http://www.curehunter.com/public/pubmed9212014.do

Adult; Aged; Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Bayes Theorem; Biomarkers, Tumor / ... Genomic test-directed chemotherapy (using the Oncotype DX 21-gene assay) was compared with chemotherapy alone (standard care) ... The study objective was to assess the cost-effectiveness of genomic test-directed chemotherapy versus chemotherapy alone for ... This study assessed the cost-effectiveness of genomic test-directed chemotherapy versus chemotherapy alone in patients with ...

https://www.crd.york.ac.uk/crdweb/ShowRecord.asp?ID=22012001735&ID=22012001735

Antineoplastic Combined Chemotherapy Protocols/therapeutic use. *Child. *Cohort Studies. *Cyclin D1/metabolism ... The combined TP53/MIPI show significant (P = 0·006) separation between low and intermediate risk groups in relation to (G) OS ... The combined TP53/MIPI show significant (P = 0·006) separation between low and intermediate risk groups in relation to (G) OS ... The combined SOX11/MIPI improves separation between low and intermediate risk groups (although, P , 0·05) in relation to (E) OS ...

https://openi.nlm.nih.gov/detailedresult.php?img=PMC4282019_bjh0166-0098-f3&req=4

Antineoplastic Combined Chemotherapy Protocols/therapeutic use. *Cell Line, Tumor. *Cell Movement/drug effects/genetics ...

https://openi.nlm.nih.gov/detailedresult.php?img=PMC4384389_13058_2015_527_Fig3_HTML&req=4

24.antineoplastic combined chemotherapy protocols 12 ƪ8.000%. 25.cell line 11 ƪ7.333% ...

http://blog.sciencenet.cn/home.php?mod=space&uid=280034&do=blog&id=1098872

Antineoplastic Combined Chemotherapy Protocols 24 * Nuclear Medicine 24 * Oncology Nursing 22 * Head and Neck Neoplasms 22 ...

https://bvsalud.org/en/direve/?filter=descriptor:Radiotherapy

Neoplasms, Medical Oncology, Radiotherapy, Antineoplastic Protocols, Antineoplastic Combined Chemotherapy Protocols, ... Antineoplastic Protocols, Antineoplastic Combined Chemotherapy Protocols, Precancerous Conditions, Genetics, Genes, Neoplasm, ... Antineoplastic Protocols, Antineoplastic Combined Chemotherapy Protocols, Precancerous Conditions, Genetics, Genes, Neoplasm, ... Antineoplastic Protocols, Antineoplastic Combined Chemotherapy Protocols, Precancerous Conditions, Cancer Symptoms, ...

https://bvsalud.org/en/direve/?filter=descriptor:General+Surgery+AND+descriptor:Neoplasms

Antineoplastic Combined Chemotherapy Protocols (1). * Carcinoma, Non-Small-Cell Lung (1) *drug therapy (1) ...

https://scholarworks.iupui.edu/handle/1805/3268/discover?filtertype_0=subject&filtertype_1=subject&filter_relational_operator_1=equals&filter_relational_operator_0=equals&filter_1=drug+therapy&filter_0=Antineoplastic+Combined+Chemotherapy+Protocols&filtertype=author&filter_relational_operator=equals&filter=Aggarwal%2C+Charu

Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use. en_US. dc.subject.mesh. Bone Marrow - Pathology. en_US. ...

http://hub.hku.hk/handle/10722/162287

Gastrointestinal cancers, Pancreatic cancer, antineoplastic combined chemotherapy protocols, lentiviral RNAi, cancer genomics, ...

https://hst.mit.edu/faculty-research/faculty/r

Antineoplastic Combined Chemotherapy Protocols Neoadjuvant Therapy Vinblastine Adjuvant Chemotherapy Non-Small Cell Lung ...

https://pennstate.pure.elsevier.com/en/organisations/department-of-medicine-2/publications/?type=%2Fdk%2Fatira%2Fpure%2Fresearchoutput%2Fresearchoutputtypes%2Fcontributiontojournal%2Feditorial&ordering=title&descending=false&page=4

Resistance to platinum-based chemotherapy remains a major impediment in the treatment of serous epithelial ovarian cancer. (nih.gov)
All 28 patients had advanced stage, high-grade serous ovarian cancer, and were treated with standard platinum-based chemotherapy. (nih.gov)
Conversely, in patients with MIBC radical cystectomy remains the corne stone of the treatment, optimally in conjunction with neoadjuvant platinum-based chemotherapy in cisplatin-eligible patients. (srce.hr)
The role of platinum-based chemotherapy as an adjuvant therapy for early stage NSCLC has been unequivocally established. (aacrjournals.org)
Patients relapsing or progressing more than 90 days after completion of first-line treatment are considered platinum sensitive and may be rechallenged with platinum-based chemotherapy. (openrepository.com)

Which alters the feeding of cancer patients, contributing to the anorexia, weight loss and malnutrition, which leads to a prognostic impact in a lower patient response to chemotherapy, radiotherapy and surgical treatment as well as increased toxic effects, impacting treatment discontinuation and therefore, morbidity and survival of patients. (clinicaltrials.gov)
Treatment options in metastatic disease range from cisplatin-based chemotherapy, immunotherapy, palliative radiotherapy and finally supportive care. (srce.hr)
Concurrent treatment with any other anticancer therapy, including chemotherapy, immunotherapy, radiotherapy (excluding radiotherapy with palliative intent on non-target lesions), targeted therapy, gene therapy, or patients planning to receive these treatments during the study. (knowcancer.com)
The treatment outcomes of this disease have improved significantly in recent years due to the improvement of diagnostic methods (pathohistology, radiology, nuclear medicine), screening and treatment improvements: surgical and oncological (chemotherapy, immunotherapy, radiotherapy). (srce.hr)
The therapeutic gain of radiotherapy may be further improved with the addition of systemic chemotherapy. (henryford.com)

DISCUSSION: This trial is the first in the world to test a remote monitoring/management intervention for adult haematological cancer patients receiving chemotherapy. (strath.ac.uk)
Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. (gu.se)

Here, we investigated the correlation between microRNA-21 expression and hepatic arterial infusion chemotherapy with 5-fluorouracil and pirarubicin (HAIC) for hepatocellular carcinoma (HCC). (nih.gov)
Conclusion: VEGF expression alone was an important marker of good response to neoadjuvant chemotherapy in patients with advanced carcinoma of the cervix. (bvsalud.org)
METHODS: We searched for English-language publications through Pubmed using a combination of the following key words: endometrial carcinoma, clear cell carcinoma, recurrence, prognosis, adjuvant therapy, radiation treatment and chemotherapy. (henryford.com)
Sixty-two patients with metastatic colorectal carcinoma involving the liver were treated by hepatic intra-arterial chemotherapy using an implantable infusion pump. (emmes.com)

We found that expression of IRS1, in contrast to IRS2, enhanced the sensitivity of 32D cells to chemotherapy-induced apoptosis. (biomedsearch.com)

However, recently, a regimen combining fluorouracil, irinotecan, oxaliplatin, and leucovorin (FOLFIRINOX) and another combining albumin-bound paclitaxel with gemcitabine have shown clear therapeutic advantage in advanced PDAC, with survival outcomes of 11.3 and 8.5 mo on phase III trials, respectively, over single-agent gemcitabine. (nih.gov)
The study cohort comprised 28 patients divided into two groups based on their varying sensitivity to first-line chemotherapy using progression free survival (PFS) as a surrogate of response. (nih.gov)
Patients treated in CR1 with SCT, autologous SCT or chemotherapy had a survival of 18 +/- 9, 5 +/- 5 and 41 +/- 5%, respectively. (diva-portal.org)
In conclusion, purine analogs, particularly combined with cyclophosphamide, significantly improve progression free survival but not survival. (ox.ac.uk)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. (lenus.ie)
CONCLUSION: Standard (non-antimetabolite) combination chemotherapy administered past the first trimester, as early as 13 weeks gestation, was associated with few complications and expected maternal survival with lymphoma occurring during pregnancy. (umassmed.edu)
PURPOSE: The addition of bevacizumab to cytotoxic chemotherapy has demonstrated a progression-free survival (PFS) benefit in the first-line and second-line treatment of advanced or metastatic breast cancer (MBC). (ox.ac.uk)
however, two long-term pilot studies suggest that IL-2 and IFNbeta, when used appropriately can have a positive effect on clinical benefit and overall survival of patients with minimal residual disease after chemotherapy or with disseminated disease controlled by conventional endocrine therapy. (nih.gov)
A preoperative ostomy and an ASA score of 3 were associated with an increased risk for "open and close" (O&C). Median survival was 11.2 months in patients treated with palliative chemotherapy (75 %) compared with 2.7 months with palliative care only. (springernature.com)
Survival in these patients is limited, but the majority could be treated with palliative chemotherapy resulting in survival of almost 1 year. (springernature.com)
2010. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. . (fredhutch.org)

Chemotherapy consisted of the sequential administration of high-dose cyclophosphamide (4 or 7 g/m 2 ) and granulocyte-colony stimulating factor (300 µg/day), followed by peripheral blood progenitor cell harvesting, administration of etoposide (2g/m 2 ) and methotrexate (8 g/m 2 only for Hodgkin's lymphoma) and autologous hematopoietic stem cell transplantation. (scielo.br)
Amsacrine is an alkylating antineoplastic agent that is highly active toward AML, unlike more conventional alkylators like cyclophosphamide. (wikipedia.org)
In this setting, it is often combined with other agents, such as: Cyclophosphamide (FLAMSA-CYC), and/or Busulfan or treosulfan (FLAMSA-BU or FLAMSA-TREO), and/or Melphalan (FLAMSA-MEL), and/or Total body irradiation, given shortly after the end of FLAMSA to prepare the patient for transplant. (wikipedia.org)

Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter? (elsevierpure.com)

In addition, PDAC cells promote a dense functional stroma that facilitates tumor resistance to chemotherapy and radiation. (nih.gov)
BACKGROUND: Combined treatment approaches targeting tumor cells as well as stromal cells may control chemorefractory malignancies. (uni-regensburg.de)
The children were followed up to 6 months after chemotherapy, and the two groups were compared in terms of visual acuity and tumor size before and after chemotherapy and adverse reactions during chemotherapy. (bvsalud.org)
[email protected]#The combined chemotherapy group had a significantly higher proportion of children achieving tumor regression than the conventional chemotherapy group (P0.05). (bvsalud.org)
Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease. (springernature.com)
Combined with castration, ganetespib displayed deeper PDX tumor regressions and delayed castration resistance relative to either monotherapy. (nih.gov)

To evaluate viral vaccine antibody levels in children with acute lymphoblastic leukemia after chemotherapy and after vaccine booster doses. (scielo.br)

Results: eighteen patients (45%) had good response to chemotherapy, and 22 (55%), poor response. (bvsalud.org)
When analyzed separately for response to chemotherapy, only the positive expression of VEGF was associated with good clinical response (p=0.0157). (bvsalud.org)

A phase II study was conducted to determine the efficacy and toxicity of combined sorafenib, docetaxel, and cisplatin in patients with metastatic or advanced adenocarcinoma of stomach or gastroesophageal junction (GEJ). (mendeley.com)
The aim of the current study was to retrospectively explore the prognosis and predictive values of TP53 somatic mutations in the BIG 02-98 randomized phase III trial in which women with node-positive breast cancer were treated with adjuvant doxorubicin-based chemotherapy with or without docetaxel. (strath.ac.uk)
This trial aims to determine if the MEK inhibitor selumetinib (AZD6244) increases the efficacy of docetaxel, a standard of care chemotherapy. (kobv.de)

With the important exception of the E4599 trial of bevacizumab in conjunction with combination chemotherapy, recent clinical trials in non-small cell lung cancer (NSCLC) that combined novel agents with standard chemotherapy have produced disappointing or equivocal results. (aacrjournals.org)
According to whether bevacizumab was used, they were divided into conventional chemotherapy (carboplatin, vincristine and etoposide) group with 12 children and combined chemotherapy (bevacizumab, carboplatin, vincristine and etoposide) group with 18 children. (bvsalud.org)
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. (cepia.team)
Bevacizumab in combination with front line chemotherapy (CT) is a standard treatment but some concern raised about tolerance of bevacizumab for these patients. (cepia.team)
Bevacizumab combined with CT was safe and efficient. (cepia.team)

89% of these patients received combination chemotherapy. (umassmed.edu)

Antibody levels against hepatitis B, rubella, measles and mumps vaccine antigens were evaluated in 33 children after completing chemotherapy (before and after vaccine booster doses) and the results were compared to the data of 33 healthy children matched for gender, age and social class. (scielo.br)

BACKGROUND: High-dose chemotherapy with tandem or triple carboplatin and etoposide course is currently the first curative choice for relapsing GCT. (unimi.it)

The objective of this study was to use gene expression profiling to delineate major deregulated pathways and biomarkers associated with the development of intrinsic chemotherapy resistance upon exposure to standard first-line therapy for ovarian cancer. (nih.gov)
Angiostatic chemotherapy consisted of trofosfamide (50 mg) administered orally 3 times daily beginning on the 15th day after the start of molecularly targeted therapy. (uni-regensburg.de)
INTERPRETATION: 10-year gains from a one-third breast cancer mortality reduction depend on absolute risks without chemotherapy (which, for oestrogen-receptor-positive disease, are the risks remaining with appropriate endocrine therapy). (ox.ac.uk)
Evidence for combined radiation therapy with systemic chemotherapy in women with advanced stage UCCC has remained debatable. (henryford.com)
In vitro combined effect of Doxorubicin and sulfonated zinc Phthalocyanine-mediated photodynamic therapy on MCF-7 breast cancer cells. (nextbio.com)

In case of relapse of aggressive lymphoma or if not obtaining CR, high dose chemotherapy with autologous stem cell support (HDT) is standard treatment. (diva-portal.org)

This retrospective analysis evaluates the clinical outcomes of SCLC patients who received SL chemotherapy after platinum-etoposide chemotherapy. (openrepository.com)

Additional studies of sorafenib with chemotherapy are warranted in gastric cancer. (mendeley.com)
This study has identified pathway specific prognostic biomarkers possibly underlying a differential chemotherapy response in patients undergoing standard platinum-based treatment of serous epithelial ovarian cancer. (nih.gov)
This study assessed the cost-effectiveness of genomic test-directed chemotherapy versus chemotherapy alone in patients with early-stage breast cancer. (york.ac.uk)
The study objective was to assess the cost-effectiveness of genomic test-directed chemotherapy versus chemotherapy alone for patients with oestrogen receptor-positive, lymph node-positive early-stage breast cancer. (york.ac.uk)
The direct costs included were treatment of recurrences and distant recurrences, terminal care, cancer treatment, out-patient care, genomic testing with Oncotype DX test, and chemotherapy-related toxicities treatment (including gut perforation, bleeding, thrombosis, allergic reactions and hypertension). (york.ac.uk)
This paper presents the protocol for a Phase 3 multi-site randomised controlled trial evaluating a novel nurse-led Telehealth intervention for remote monitoring/management of chemotherapy side-effects in Australian haematological cancer patients. (strath.ac.uk)
The phase III CONFIRM clinical trials demonstrated that metastatic colorectal cancer patients with elevated serum lactate dehydrogenase (LDH) had improved outcome when the vascular endothelial growth factor receptor (VEGFR) inhibitor PTK/ZK (Vatalanib) was added to FOLFOX4 chemotherapy. (qub.ac.uk)
Lenz, H-J. / Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib) . (qub.ac.uk)
BACKGROUND: Moderate differences in efficacy between adjuvant chemotherapy regimens for breast cancer are plausible, and could affect treatment choices. (ox.ac.uk)
PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial. (cepia.team)
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. (openrepository.com)
Patients with small-cell lung cancer (SCLC) that progress after first-line chemotherapy have a poor prognosis and the evidence of a benefit from second-line (SL) chemotherapy is limited. (openrepository.com)

ABSTRACT Objective: to analyze the expression of Vascular Endothelial Growth Factor (VEGF), its receptor (VEGFR-2), age and histological type of advanced cervical carcinomas with respect to the clinical response to neoadjuvant chemotherapy. (bvsalud.org)
All patients underwent neoadjuvant chemotherapy and evaluation for clinical response and expression of VEGF. (bvsalud.org)

The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations. (lenus.ie)
Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma]. (lenus.ie)

To determine the role of IRS1 and IRS2 in the sensitivity of cells to chemotherapy, we treated 32D cells lacking or expressing IRS proteins with various concentrations of chemotherapeutic agents. (biomedsearch.com)

PATIENTS AND METHODS: Forty-four chemotherapy-naïve patients with Eastern Cooperative Oncology Group performance status 0 or 1, of whom 80% had metastatic disease and two thirds had poorly differentiated gastric or GEJ adenocarcinoma, were enrolled. (mendeley.com)
METHODS: A Phase II trial was initiated to analyze the activity of a continuously administered molecularly targeted treatment regimen (daily pioglitazone [45 mg administered orally] and rofecoxib [25 mg administered orally]) combined with sequentially added angiostatic chemotherapy for patients with previously treated metastatic melanoma (n = 19) or soft tissue sarcoma (n = 21). (uni-regensburg.de)
[email protected]#A retrospective analysis was performed for the clinical data of 30 children with OPG who underwent chemotherapy. (bvsalud.org)

The objective of this study is to describe the threshold of perception and recognition of basic tastes in patients with NSCLC before treatment with platin and paclitaxel-based chemotherapy and after the second cycle, and analyze the effect in the developement of dysgeusia, as well as the association between these and the nutritional status and quality of life. (clinicaltrials.gov)

001). In patients with t(15;17) treated with extended all-trans retinoic acid and anthracycline-based chemotherapy, additional cytogenetic changes did not have an impact on prognosis. (nih.gov)

Patients will be randomised 1:1 to either the control or intervention arm with stratification by diagnosis, chemotherapy toxicity (high versus low), receipt of previous chemotherapy and hospital. (strath.ac.uk)
and polychemotherapy versus no chemotherapy (n=32,000). (ox.ac.uk)

However, this treatment modality is fraught with difficulties associated with toxicity and also the emergence of chemotherapy resistance is a considerable problem. (surrey.ac.uk)

CONCLUSIONS: To our knowledge, the current study is the first to demonstrate that a novel, completely orally administered combined biomodulator/metronomic chemotherapy regimen may be active and well tolerated in patients with chemorefractory malignancies. (uni-regensburg.de)
FLAG is a chemotherapy regimen used for relapsed and refractory acute myeloid leukemia (AML). (wikipedia.org)
The FLAMSA protocol is most often used as an induction part of a reduced-intensity conditioning regimen for patients eligible to undergo an allogeneic stem cell transplant. (wikipedia.org)

Furthermore, we explored the possibility of creating an improved prognostic tool by combining the MIPI with information on molecular markers.SOX11 was shown to significantly add prognostic information to the MIPI, but in multivariate analysis TP53 was the only significant independent molecular marker.Based on these findings, we propose that TP53 and SOX11 should routinely be assessed and that a combined TP53/MIPI score may be used to guide treatment decisions. (nih.gov)
Taken together, our findings demonstrate that microRNA-21 is a chemotherapy responsive microRNA and can serve as a prognostic biomarker for HCC patients undergoing HAIC. (nih.gov)

Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit. (wakehealth.edu)

Combining bortezomib and cisplatin further decreased cell viability both in vitro and in vivo that single agent bortezomib treatment. (nih.gov)

Anatomy5

Organisms6

Diseases59

Chemicals and Drugs84

Analytical, Diagnostic and Therapeutic Techniques and Equipment70

Phenomena and Processes18

Disciplines and Occupations4

Anthropology, Education, Sociology and Social Phenomena1

Technology, Industry, Agriculture4

Humanities1

Information Science2

Named Groups2

Health Care35

Tumour ablation and hepatic decompensation rates in multi-agent chemoembolization of hepatocellular carcinoma. (1/20433)

Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). (2/20433)

Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. (3/20433)

Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. (4/20433)

Patterns of care and survival for adolescents and young adults with acute leukaemia--a population-based study. (5/20433)

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (6/20433)

Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. (7/20433)

Central venous catheter exchange by guidewire for treatment of catheter-related bacteraemia in patients undergoing BMT or intensive chemotherapy. (8/20433)

Antineoplastic Combined Chemotherapy Protocols

Antineoplastic Agents

Doxorubicin

Cyclophosphamide

Osteosarcoma

Combined Modality Therapy

Cisplatin

Disease-Free Survival

Vincristine

Treatment Outcome

Chemotherapy, Adjuvant

Prognosis

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Retrospective Studies

Clinical Protocols

Antibiotics, Antineoplastic

Antineoplastic Agents, Phytogenic

Etoposide

Breast Neoplasms

Neoplasms

Neoadjuvant Therapy

Antineoplastic Agents, Alkylating

Drug Administration Schedule

Paclitaxel

Antimetabolites, Antineoplastic

Lung Neoplasms

Methotrexate

Survival Analysis

Neoplasm Staging

Survival Rate

Drug Resistance, Neoplasm

Vinblastine

Carboplatin

Bleomycin

Time Factors

Taxoids

Cell Line, Tumor

Ifosfamide

Cytarabine

Organoplatinum Compounds

Induction Chemotherapy

Drug Screening Assays, Antitumor

Dose-Response Relationship, Drug

Deoxycytidine

Neoplasm Recurrence, Local

Anthracyclines

Apoptosis

Ovarian Neoplasms

Daunorubicin

Clinical Trials as Topic

Neoplasm Metastasis

Carmustine

Follow-Up Studies

Adenocarcinoma

Carcinoma, Non-Small-Cell Lung

Vomiting

Tumor Cells, Cultured

Nausea

Camptothecin

Drug Synergism

Lymphoma, Non-Hodgkin

Colorectal Neoplasms

Neutropenia

Chemotherapy, Cancer, Regional Perfusion

Salvage Therapy

Lomustine

Cell Survival

Mitomycin

Radiotherapy

Brain Neoplasms

Prospective Studies

Dacarbazine

Infusions, Intravenous

Melphalan

Transplantation, Autologous

Bone Neoplasms

Testicular Neoplasms

Leukopenia

Radiotherapy, Adjuvant

Leukemia P388